Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

Author(s):
Badrising, S.K.; Noort, V. van der; Hamberg, P.; Coenen, J.L.L.M.; Aarts, M.J.; Oort, I.M. van; Eertwegh, A.J.M. van den; ; Berg, H.P. van den; Gelderblom, H.; Vrijaldenhoven, S.; Kerver, E.D.; Voorthuizen, T. van; Jong, I.J. de; Haanen, J.B.; Bergman, A.M.; Dutch Uro-Oncol Study Grp DUOS
Published
2016
Publication type
Article / Letter to editor
Cross-resistanceTreatment sequenceHeavily pretreated patientsTime intervalDocetaxelAbirateroneCabazitaxelRadium-223
Date issued
2016-12-31
Language
English
Is part of
Oncology (2016), Vol. 91, no. 5, p. 267-273
hdl
1887/112894
doi
10.1159/000448219